Новости мировой тиреоидологии (№2 2015)

Представлены абстракты актуальных международных исследований, посвященных диагностике и лечению различной пато- логии щитовидной железы, а также влиянию на нее сопутствующих состояний.

Ритуксимаб, эндокринная орбитопатия, болезнь Грейвса, тиреотоксикоз, гипотиреоз, неонатальный тиреотоксикоз, гестационный тиреотоксикоз, рак щитовидной железы

1. Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with Rituximab in patients with active moderate to severe Graves’ orbitopathy: A randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422-431. doi: 10.1210/jc.2014-3014.

2. Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized con- trolled trial of Rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432-441. doi: 10.1210/jc.2014-2572.

3. Liu X, Qiang W, Liu X, et al. A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in chinese patients with Graves’ disease. Exp Clin Endocrinol Diabetes. 2014;122(10):564-567. doi: 10.1055/s-0034-1377045.

4. Besancon A, Beltrand J, Le Gac I, et al. Management of neonates born to women with Graves’ disease: a cohort study. Eur J Endocrinol. 2014;170(6):855-862. doi: 10.1530/eje-13-0994.

5. Ma L, Qi H, Chai X, et al. The effects of screening and intervention of subclinical hypothyroidism on pregnancy outcomes: a prospec- tive multicenter single-blind, randomized, controlled study of thy- roid function screening test during pregnancy. J Matern Fetal Neonatal Med. 2015:1-4. doi: 10.3109/14767058.2015.1049150.

6. Kornelius E, Chiou J-Y, Yang Y-S, et al. Iodinated contrast media increased the risk of thyroid dysfunction: A 6-year retrospective cohort study. J Clin Endocrinol Metab. 2015:JC.2015-2329. doi: 10.1210/jc.2015-2329.

7. Busnelli A, Vannucchi G, Paffoni A, et al. Levothyroxine dose adjustment in hypothyroid women achieving pregnancy through IVF. Eur J Endocrinol. 2015:EJE-15-0151. doi: 10.1530/eje-15- 0151.

8. Eugenin EA, Andersen MN, Olsen A-MS, et al. Levothyroxine substitution in patients with subclinical hypothyroidism and the risk of myocardial infarction and mortality. PLoS ONE. 2015; 10(6):e0129793. doi: 10.1371/journal.pone.0129793.

9. Sung T-Y, Lee Y-m, Yoon JH, et al. Long-term effect of surgery in Graves’ disease: 20 years experience in a single institution. Int J Endocrinol. 2015;2015:1-6. doi: 10.1155/2015/542641.

10. Manavela M, Vigovich C, Danilowicz K, et al. Thyroid autoim- mune disorders in patients with acromegaly. Pituitary. 2015. doi: 10.1007/s11102-015-0670-5.

11. Nakamura H, Hirokawa M, Ota H, et al. Is an increase in thyroid nodule volume a risk factor for malignancy? Thyroid. 2015;25(7):804-811. doi: 10.1089/thy.2014.0567.

12. Lo JC, Rivkees SA, Chandra M, et al. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid. 2015;25(6):698-705. doi: 10.1089/thy.2014.0434.

13. Zamora-Ros R, Rinaldi S, Tsilidis KK, et al. Energy and macronu- trient intake and risk of differentiated thyroid carcinoma in the European Prospective Investigation into Cancer and Nutrition study. Int J Cancer. 2015:n/a-n/a. doi: 10.1002/ijc.29693.

14. Kelderman-Bolk N, Visser TJ, Tijssen JGp, Berghout A. Quality of life in patients with primary hypothyroidism is related to BMI. Eur J Endocrinol. 2015:EJE-15-0395. doi: 10.1530/eje-15-0395.

15. Martin S, Sirbu A, Betivoiu M, et al. IGF1 deficiency in newly diagnosed Graves’ disease patients. Hormones. 2015. doi: 10.14310/horm.2002.1577.